Beyond Air, Inc. (XAIR)
| Market Cap | 5.69M -67.1% |
| Revenue (ttm) | 6.92M +129.0% |
| Net Income | -31.00M |
| EPS | -5.06 |
| Shares Out | 13.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,233 |
| Open | 0.4244 |
| Previous Close | 0.4375 |
| Day's Range | 0.4166 - 0.4488 |
| 52-Week Range | 0.3810 - 5.8420 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 8.67 (+1,911.13%) |
| Earnings Date | Jun 16, 2026 |
About XAIR
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for ... [Read more]
Financial Performance
In fiscal year 2025, Beyond Air's revenue was $3.71 million, an increase of 219.67% compared to the previous year's $1.16 million. Losses were -$46.63 million, -22.60% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for XAIR stock is "Buy." The 12-month stock price target is $8.67, which is an increase of 1,911.13% from the latest price.
News
Beyond Air Proxy statement: Proxy filing
Beyond Air filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Beyond Air Proxy statement: Proxy filing
Beyond Air filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Beyond Air’s Beyond Cancer reports updated data from Phase 1 UNO trial
Beyond Cancer, a subsidiary of Beyond Air (XAIR), announced updated follow-up data from its Phase 1 UNO trial, which are being presented at the American Association for Cancer Research, AACR,…
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (...
Beyond Air CEO Steve Lisi resigns, Robert Goodman succeeds
Beyond Air (XAIR) announced that Steve Lisi has resigned as CEO and stepped down from the board of directors, effective March 27 to pursue other opportunities. The board of directors…
Beyond Air subsidiary reports signs of clinical activity from UNO trial
Beyond Cancer, a subsidiary of Beyond Air (XAIR), announced early signs of clinical activity and a favorable safety and tolerability profile from its Phase 1 clinical trial evaluating a single…
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th Data was published in the Online Itinerary Planner fo...
Beyond Air Transcript: Life Sciences Virtual Investor Forum
Nitric oxide delivery technology is expanding globally, with FDA and CE mark approvals and a second-generation system expected to drive further growth. Quarterly revenue rose 105% year-over-year, and international expansion is underway, with new clinical data in cancer to be presented soon.
Beyond Air announces termination of NeuroNOS agreement with XTL
Beyond Air (XAIR) announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals (XTLB) relating to Beyond Air’s NeuroNOS subsidiary has been terminated. The companies entere...
Beyond Air announces publication of review article on effects of iNO
Beyond Air (XAIR) commented on the publication of an independent review article providing the most comprehensive overview to date of high-dose inhaled nitric oxide, iNO, delivered at concentrations we...
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air price target lowered to $2 from $6 at JonesResearch
JonesResearch lowered the firm’s price target on Beyond Air (XAIR) to $2 from $6 and keeps a Buy rating on the shares following the fiscal Q3 report. The potential commercialization…
Beyond Air Earnings Call Transcript: Q3 2026
Revenue doubled year-over-year to $2.2M, with strong hospital adoption and improved gross margin. Operating expenses and net loss declined significantly, and recent financings extend cash runway into 2027. Gen 2 LungFit PH approval is expected by end of 2026.
Beyond Air Earnings release: Q3 2026
Beyond Air released its Q3 2026 earnings on February 13, 2026, summarizing the period's financial results.
Beyond Air Quarterly report: Q3 2026
Beyond Air has published its Q3 2026 quarterly earnings report on February 13, 2026.
Beyond Air reports Q3 EPS (85c) vs ($2.96) last year
Reports Q3 revenue $2.19M, consensus $2.15M. “We exceeded $2.0 million in quarterly revenue which marks an important milestone as we continue scaling our business and building awareness of the benefit...
Beyond Air sees FY26 revenue $8M-$10M, consensus $8.28M
The Company maintained its revenue guidance of $8-10 million for the fiscal year ending March 31, 2026.
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash ...
Beyond Air Slides: Corporate presentation
Beyond Air has posted slides in relation to its latest quarterly earnings report, which was published on February 13, 2026.
Beyond Air files to sell 7.86M shares of common stock for holders
16:05 EST Beyond Air (XAIR) files to sell 7.86M shares of common stock for holders
Beyond Air Registration statement: Registration Filing
Beyond Air filed a registration statement on January 30, 2026, providing details about a securities offering with the SEC.
XTL Biopharmaceuticals provides update on recent developments
XTL Biopharmaceuticals (XTLB) announced that it is working to close the acquisition of 85% of the shares of NeuroNOS from Beyond Air (XAIR) following the execution of the binding letter…
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Beyond Air (XAIR) with a Buy rating and $5 price target